December 2, 1991European Heart Journal
Calcium channel blockers and ischaemic heart disease: theoretical expectations and clinical experience
Key result
Calcium antagonists administered after the signs of myocardial infarction generally do not reduce infarct size or decrease mortality, with diltiazem and verapamil being recent exceptions.
Why the study?
Do calcium channel blockers protect ischaemic myocardium and improve outcomes in patients with coronary artery disease?
Population
Patients with coronary artery disease (CAD) and experimental models of ischaemic and reperfused myocytes
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Calcium antagonists post-MI do not warrant routine use to limit infarct size or mortality; leaves open potential benefits with diltiazem or verapamil.
Structured PICO
Do calcium channel blockers protect ischaemic myocardium and improve outcomes in patients with coronary artery disease?
P
Population
Patients with coronary artery disease (CAD) and experimental models of ischaemic and reperfused myocytes
I
Intervention
Calcium channel blockers (calcium antagonists, including phenylalkylamines, benzothiazepines, diltiazem, and verapamil)
Calcium channel blockers offer theoretical and experimental myocardial protection when given before ischaemia, but generally lack clinical benefit in reducing infarct size or mortality when given after myocardial infarction, with some exceptions.
Cite This Study
Ferrari et al. (1991) conducted a review in Ischaemic heart disease. Calcium channel blockers was evaluated. Calcium antagonists administered after the signs of myocardial infarction generally do not reduce infarct size or decrease mortality, with diltiazem and verapamil being recent exceptions.